Aspirin-free antiplatelet regimens after PCI: when is it best to stop aspirin and who could ultimately benefit?

Mariusz Tomaniak; Robert F. Storey; Patrick W. Serruys

doi:10.4244/eijy19m10_01

Related publications

Article2021

Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond

Rutao Wang, Sijing Wu, Amr Gamal, Chao Gao, Hironori Hara, Hideyuki Kawashima, Masafumi Ono, Robert‐Jan van Geuns, Pascal Vranckx, Stephan Windecker, Yoshinobu Onuma, Patrick W. Serruys, Scot Garg

European Heart Journal - Cardiovascular Pharmacotherapy

Article2017

Single or dual antiplatelet therapy after PCI

Yosuke Miyazaki, Pannipa Suwannasom, Yohei Sotomi, Mohammad Abdelghani, Karthik Tummala, Yuki Katagiri, Taku Asano, Erhan Tenekecioğlu, Yaping Zeng, Rafael Cavalcante, Carlos Collet, Yoshinobu Onuma, Patrick W. Serruys

Nature Reviews Cardiology

Letter2020

Twilight, the Dawn of a New Era of Aspirin-Free PCI?

Patrick W. Serruys, Kuniaki Takahashi, Ply Chichareon, Yoshinobu Onuma

Journal of the American College of Cardiology

Article2024

TCT-231 Safety of Aspirin-Free Prasugrel Monotherapy After PCI: Pooled Analysis of Three Months Outcomes in 508 Patients From ASET-I and ASET-Japan Trials

Kotaro Miyashita, Takashi Muramatsu, Gaku Nakazawa, Yuki Ishibashi, Yoshinobu Onuma, Pedro A. Lemos, Patrick W. Serruys

Journal of the American College of Cardiology

Editorial Material2017

What is it to become an octogenarian 40 years after the first angioplasty?

Patrick W. Serruys, Yoshinobu Onuma

EuroIntervention